PureTech Health PLC
PRTC18.260USD
-0.829-4.34%
Trading geöffnet （ET）Kurse um 15 Minuten verzögert
4.37BMarktkapitalisierung
--KGV TTM
mehr Informationen über PureTech Health PLC Unternehmen
PureTech Health plc is a clinical stage biotherapeutics company dedicated to giving life to new classes of medicine to change the lives of patients with devastating diseases. The Company's R&D engine has resulted in the development of around 29 therapeutics and therapeutic candidates, including two that have received both United States Food and Drug Administration (FDA) clearance and European marketing authorization and a third (KarXT) that has been filed for FDA approval. Its product candidates include LYT-100, LYT-200, SPT-300, SPT-310 and SPT-320. LYT-100 (deupirfenidone) is being developed internally by the Company for the treatment of idiopathic pulmonary fibrosis (IPF). LYT-200 is being developed for the treatment of hematological malignancies, such as acute myeloid leukemia and high-risk myelodysplastic syndromes, as well as locally advanced/metastatic solid tumors. SPT-300 is an oral prodrug of allopregnanolone, which is being advanced for the treatment of anxious depression.
Unternehmensinformationen
BörsenkürzelPRTC
Name des UnternehmensPureTech Health PLC
IPO-datumJun 19, 2015
CEOMr. Robert (Rob) Lyne
Anzahl der mitarbeiter56
WertpapierartOrdinary Share
GeschäftsjahresendeJun 19
Addresse6 Tide Street
StadtBOSTON
BörseLondon Stock Exchange
LandUnited States of America
Postleitzahl02210
Telefon16174822333
Websitehttps://puretechhealth.com/
BörsenkürzelPRTC
IPO-datumJun 19, 2015
CEOMr. Robert (Rob) Lyne
Führungskräfte
Name
Name/Position
Position
Aktienbesitz
Veränderung
Ms. Kiran Mazumdar-Shaw
Ms. Kiran Mazumdar-Shaw
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Ms. Sharon Barber-lui
Ms. Sharon Barber-lui
Interim Independent Non-Executive Chairman of the Board
Interim Independent Non-Executive Chairman of the Board
--
--
Dr. Michele A. M. Holcomb, Ph.D.
Dr. Michele A. M. Holcomb, Ph.D.
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Langer (Robert S Jr)
Langer (Robert S Jr)
Co-Founder, Non-Executive Director
Co-Founder, Non-Executive Director
--
--
Dr. John L. Lamattina, Ph.D.
Dr. John L. Lamattina, Ph.D.
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Dr. Eric Elenko, Ph.D.
Dr. Eric Elenko, Ph.D.
President, Director
President, Director
--
--
Mr. Robert (Rob) Lyne
Mr. Robert (Rob) Lyne
Interim Chief Executive Officer
Interim Chief Executive Officer
--
--
Dr. Charles H. Sherwood, Ph.D.
Dr. Charles H. Sherwood, Ph.D.
General Counsel, Company Secretary
General Counsel, Company Secretary
--
--
Mr. Robert J. (Bob) Hombach, CPA
Mr. Robert J. (Bob) Hombach, CPA
Director
Director
--
--
Name
Name/Position
Position
Aktienbesitz
Veränderung
Ms. Kiran Mazumdar-Shaw
Ms. Kiran Mazumdar-Shaw
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Ms. Sharon Barber-lui
Ms. Sharon Barber-lui
Interim Independent Non-Executive Chairman of the Board
Interim Independent Non-Executive Chairman of the Board
--
--
Dr. Michele A. M. Holcomb, Ph.D.
Dr. Michele A. M. Holcomb, Ph.D.
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Langer (Robert S Jr)
Langer (Robert S Jr)
Co-Founder, Non-Executive Director
Co-Founder, Non-Executive Director
--
--
Dr. John L. Lamattina, Ph.D.
Dr. John L. Lamattina, Ph.D.
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Dr. Eric Elenko, Ph.D.
Dr. Eric Elenko, Ph.D.
President, Director
President, Director
--
--
Umsatzaufteilung
Keine Daten
Keine Daten
Nach Geschäftsbereich
Nach Region
Keine Daten
Aktionärsstatistik
Aktualisiert: Mon, Jun 2
Aktualisiert: Mon, Jun 2
Aktionäre
Aktionärstypen
Aktionäre
Aktionäre
Anteil
Birch Hill Investment Advisors LLC
1.01%
Millennium Management LLC
0.19%
Pentwater Capital Management LP
0.14%
Portolan Capital Management, L.L.C.
0.05%
Other
98.62%
Aktionäre
Aktionäre
Anteil
Birch Hill Investment Advisors LLC
1.01%
Millennium Management LLC
0.19%
Pentwater Capital Management LP
0.14%
Portolan Capital Management, L.L.C.
0.05%
Other
98.62%
Aktionärstypen
Aktionäre
Anteil
Investment Advisor
1.26%
Hedge Fund
0.33%
Investment Advisor/Hedge Fund
0.05%
Other
98.36%
Institutionelle Beteiligung
Aktualisiert: Tue, Jul 1
Aktualisiert: Tue, Jul 1
Berichtszeitraum
Anzahl der Institutionen
Gehaltenen Aktien
Anteil
Veränderung
2025Q2
15
335.52K
1.39%
-63.86K
2025Q1
14
393.56K
1.64%
-4.75K
2024Q4
14
374.87K
1.56%
+317.90K
2024Q3
13
30.04K
0.13%
-317.21K
2024Q2
12
323.23K
1.35%
+280.87K
2024Q1
9
25.15K
0.09%
-3.71K
2023Q4
10
11.40K
0.04%
-82.93K
2023Q3
12
84.27K
0.31%
-16.31K
2023Q2
11
83.51K
0.30%
-16.43K
2023Q1
13
82.93K
0.30%
-317.41K
Mehr Anzeigen
Aktionärsaktivitäten
Name
Gehaltenen Aktien
Anteil
Veränderung
Änderung%
Datum
Birch Hill Investment Advisors LLC
302.00K
1.25%
--
--
Mar 31, 2025
Millennium Management LLC
44.91K
0.19%
-353.00
-0.78%
Mar 31, 2025
Pentwater Capital Management LP
33.56K
0.14%
+9.45K
+39.19%
Mar 31, 2025
Portolan Capital Management, L.L.C.
11.88K
0.05%
+11.88K
--
Mar 31, 2025
Fidelity Management & Research Company LLC
1.28K
0.01%
--
--
May 31, 2025
Geode Capital Management, L.L.C.
770.00
0%
--
--
May 31, 2025
Dimensional Fund Advisors, L.P.
316.00
0%
-208.00
-39.69%
Mar 31, 2025
Morgan Stanley Smith Barney LLC
100.00
0%
--
--
Mar 31, 2025
UBS Financial Services, Inc.
20.00
0%
-1.88K
-98.95%
Mar 31, 2025
Dimensional Fund Advisors, Ltd.
--
0%
-196.00
-100.00%
Jan 31, 2025
Mehr Anzeigen
Verbundene ETFs
Name
Anteil
Keine Daten
Dividende
In den vergangenen 5 Jahren wurden insgesamt
0.00
USD an Dividenden ausgeschüttet.
Datum
Dividende
Stichtag für die Aktienregistrierung
Zahltag
Ex-Dividendentag
Keine Daten
Aktien-Split
Datum
Art
Verhältnis
Keine Daten
Datum
Art
Verhältnis
Keine Daten
